Drug Trial Radar · NCT04938817
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Aug 19, 2021
Primary completion
Dec 10, 2029
Study completion Dec 10, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Jun 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an initial safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D) followed by an efficacy evaluation. Investigational agents will initiate directly in or be added to the efficacy evaluation after an initial evaluation of safety and tolerability of the investigational agent has been completed in a separate study or in the safety lead-in of this study. If an RP2D for a combination being evaluated in the safety lead-in is established from another study, then the efficacy evaluation may begin at the determined RP2D. There will be no hypothesis testing in this study.
Conditions
- Small Cell Lung Carcinoma
Interventions
coformulation pembrolizumab/quavonlimabBiological
Intravenous (IV) infusion
lenvatinibDrug
Oral administration
MK-4830Biological
IV infusion
coformulation favezelimab/pembrolizumabBiological
IV infusion
R-DXdBiological
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)Time frame: Up to 21 days in Cycle 1 (Cycle 1 = 21 days)
- Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 60 months
- Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 60 months
- Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to approximately 60 months
Locations
48 sites in 12 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center ( Site 0152)
Gilbert, Arizona
Northside Hospital-Northside Hospital Oncology Network ( Site 0156)
Atlanta, Georgia
Parkview Research Center at Parkview Regional Medical Center ( Site 0180)
Fort Wayne, Indiana
Baptist Health Lexington-Research ( Site 0158)
Lexington, Kentucky
University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0157)
Lexington, Kentucky
MFSMC-HJWCI-Oncology Research ( Site 0178)
Baltimore, Maryland
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0172)
Omaha, Nebraska
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0179)
Omaha, Nebraska
Cleveland Clinic-Taussig Cancer Center ( Site 0166)
Cleveland, Ohio
UPMC Hillman Cancer Center ( Site 0177)
Pittsburgh, Pennsylvania
St Francis Cancer Center-Research Office ( Site 0167)
Greenville, South Carolina
Virginia Cancer Institute ( Site 0169)
Richmond, Virginia
Westmead Hospital-Department of Medical Oncology ( Site 4004)
Westmead, New South Wales, Australia
The Prince Charles Hospital-Oncology Clinical Trials ( Site 4003)
Brisbane, Queensland, Australia
Monash Health-Oncology Research ( Site 4005)
Clayton, Victoria, Australia
Hollywood Private Hospital-Medical Oncology ( Site 4001)
Perth, Western Australia, Australia
Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 3101)
Vienna, Austria
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 3100)
Vienna, Austria
Cross Cancer Institute ( Site 3004)
Edmonton, Alberta, Canada
Princess Margaret Cancer Centre ( Site 3003)
Toronto, Ontario, Canada
St. Marys Hospital Center ( Site 3000)
Montreal, Quebec, Canada
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 3800)
Szolnok, Jász-Nagykun-Szolnok, Hungary
Rambam Health Care Campus-Oncology ( Site 3600)
Haifa, Israel
Shaare Zedek Medical Center-Oncology ( Site 3602)
Jerusalem, Israel
Meir Medical Center. ( Site 3601)
Kfar Saba, Israel
Rabin Medical Center-Oncology ( Site 3604)
Petah Tikva, Israel
Sheba Medical Center-ONCOLOGY ( Site 3603)
Ramat Gan, Israel
Ospedale San Raffaele-Oncologia Medica ( Site 3303)
Milan, Italy
Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 3304)
Milan, Italy
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 3301)
Rozzano, Milano, Italy
ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 3300)
Siena, Tuscany, Italy
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 3900)
Warsaw, Masovian Voivodeship, Poland
Warminsko-Mazurskie Centrum Chorob Płuc w Olsztynie ( Site 3903)
Olsztyn, Warmian-Masurian Voivodeship, Poland
Scientific research institution of oncology named after N.N. Petrov-Thoracic oncology ( Site 3704)
Saint Petersburg, Russia
Krasnoyarsk Regional Oncology Dispensary, Named after Krizhanovsky ( Site 3708)
Krasnoyarsk, Krasnoyarsk Krai, Russia
Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 3702)
Saint Petersburg, Leningradskaya Oblast', Russia
GBUZ LOKB-Oncology department #1 ( Site 3701)
Saint Petersburg, Sankt-Peterburg, Russia
GBUZ "SPb CRPCstmc(o)" ( Site 3705)
Saint Petersburg, Sankt-Peterburg, Russia
N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( Site 3703)
Saint Petersburg, Sankt-Peterburg, Russia
Seoul National University Hospital ( Site 4101)
Seoul, South Korea
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.